- Home
- ASMB vs EURK Comparison
ASMB vs EURK Comparison
Compare ASMB & EURK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- EURK
- Stock Information
- Founded
- ASMB 2005
- EURK 2023
- Country
- ASMB United States
- EURK Hong Kong
- Employees
- ASMB N/A
- EURK N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- EURK
- Sector
- ASMB Health Care
- EURK
- Exchange
- ASMB Nasdaq
- EURK NYSE
- Market Cap
- ASMB 84.5M
- EURK 80.0M
- IPO Year
- ASMB 2010
- EURK 2024
- Fundamental
- Price
- ASMB $10.61
- EURK $10.27
- Analyst Decision
- ASMB Buy
- EURK
- Analyst Count
- ASMB 2
- EURK 0
- Target Price
- ASMB $35.00
- EURK N/A
- AVG Volume (30 Days)
- ASMB 27.4K
- EURK 18.4K
- Earning Date
- ASMB 05-07-2025
- EURK 01-01-0001
- Dividend Yield
- ASMB N/A
- EURK N/A
- EPS Growth
- ASMB N/A
- EURK N/A
- EPS
- ASMB N/A
- EURK N/A
- Revenue
- ASMB $28,326,000.00
- EURK N/A
- Revenue This Year
- ASMB $282.16
- EURK N/A
- Revenue Next Year
- ASMB N/A
- EURK N/A
- P/E Ratio
- ASMB N/A
- EURK N/A
- Revenue Growth
- ASMB N/A
- EURK N/A
- 52 Week Low
- ASMB $10.56
- EURK $10.03
- 52 Week High
- ASMB $19.93
- EURK $10.27
- Technical
- Relative Strength Index (RSI)
- ASMB 30.74
- EURK N/A
- Support Level
- ASMB $10.56
- EURK N/A
- Resistance Level
- ASMB $11.41
- EURK N/A
- Average True Range (ATR)
- ASMB 0.75
- EURK 0.00
- MACD
- ASMB -0.10
- EURK 0.00
- Stochastic Oscillator
- ASMB 1.68
- EURK 0.00
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About EURK EUREKA ACQUISITION CORP
Eureka Acquisition Corp is a newly incorporated blank check company.